Get the Stockscreener App
6.87
3.62%
0.24
Helus Pharma Inc stock is traded at $6.87, with a volume of 1.52M.
It is up +3.62% in the last 24 hours and up +77.52% over the past month.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
See More
Previous Close:
$6.63
Open:
$6.6
24h Volume:
1.52M
Relative Volume:
1.28
Market Cap:
$425.83M
Revenue:
-
Net Income/Loss:
$-122.31M
P/E Ratio:
-1.5216
EPS:
-4.5151
Net Cash Flow:
$-110.41M
1W Performance:
+10.10%
1M Performance:
+77.52%
6M Performance:
-8.76%
1Y Performance:
+0.00%
1-Day Range:
$6.38
$6.97
1-Week Range:
$5.77
$6.97
52-Week Range:
$3.76
$8.5498
Helus Pharma Inc Stock (HELP) Company Profile
Compare HELP vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HELP
Helus Pharma Inc
|
6.87 | 425.83M | 0 | -122.31M | -110.41M | -4.5151 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Helus Pharma Inc Stock (HELP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-13-26 | Initiated | TD Cowen | Buy |
| Feb-02-26 | Initiated | Jefferies | Buy |
| Mar-13-25 | Initiated | Guggenheim | Buy |
| Nov-19-21 | Downgrade | Maxim Group | Buy → Hold |
Helus Pharma Inc Stock (HELP) Latest News
HELP News Today | Why did Cybin stock go up today? $HELP - MarketBeat
H.C. Wainwright cuts Helus Pharma stock price target to $70 on dilution By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Helus Pharma stock price target to $70 on dilution - Investing.com Canada
HELP Stock Price, Quote & Chart - ChartMill
HELP Maintained by Canaccord Genuity -- Price Target Lowered to $42.00 - GuruFocus
Canaccord lowers Helus Pharma stock price target on valuation By Investing.com - Investing.com Canada
symbol__ Stock Quote Price and Forecast - CNN
HELP Stock Crashes On Anxiety Trial Results, But Here’s Why Jefferies Sees Up To 200% Upside - Stocktwits
Helus Pharma prices $50M public offering at $4.85 per share - MSN
Helus Pharma reports cash position and pipeline progress - grafa.com
HELPHelus Pharma Inc Latest SEC Filings - Finviz
Press Release: Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial Results - Moomoo
Cybin : MDA Q4 26 (Exhibit 99.3) Final - marketscreener.com
Helus Pharma reports Phase 3 trial progress, closes $50M offering - Investing.com Canada
Helus Pharma Reports Recent Business Highlights and Fiscal Year 2026 Financial ResultsMon, 06/29/202607:40 - Helus Pharma
Helus Pharma’s lead trial nears readout as cash hits $157.3M - Stock Titan
Cybin Inc. (HELP) Form 40-F: 51.63M shares, governance disclosures - Stock Titan
Cybin (HELP) As Phase 3 Enrollment Progresses, The Undervalued Narrative Holds - simplywall.st
Helus Pharma (HELP) Stock Analysis Report | Financials & Insights - Benzinga
Cybin: A Speculative Bet On Their Pivotal Depression Readout (NASDAQ:HELP) - Seeking Alpha
Helus Pharma's HLP003 Phase 3 results expected in Q4 2026, backed by strong funding and no debt. - Pluang
Cybin (HELP) Is Up 28.9% After Phase 3 HLP003 Progress And $50M Equity RaiseHas The Bull Case Changed? - Yahoo Finance
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year - Investing News Network
Cybin (HELP) Is Up 28.9% After HLP003 Phase 3 Enrollment Surpasses 86% in MDD Trial - simplywall.st
Helus Pharma™ Announces Closing of US$50 Million Underwritten OfferingThu, 06/25/202609:28 - Helus Pharma
Helus Pharma Raises US$50 Million to Advance Late-Stage Mental Health Drug Pipeline - TipRanks
Helus Pharma (Nasdaq: HELP) raises US$50M to fund NSA pipeline - Stock Titan
Helus Pharma raises US$50M to fund Phase 3 and anxiety programs - Stock Titan
Helus Pharma Prices US$50 Million Equity Offering to Advance Mental Health Drug Pipeline - TipRanks
Helus Pharma (HELP) prices US$50M share sale to fund Phase 3 MDD trial - Stock Titan
HELP Stock Price and Chart — NEO:HELP - TradingView
To Wall Street, psychedelics biotechs are more teammates than rivals - BioPharma Dive
Helus Pharma surpasses 86% enrollment in Phase 3 trial of HLP003 for depression - grafa.com
Cybin (HELP) FDA Approvals, PDUFA Dates & Drug Alerts 2026 $HELP - MarketBeat
Helus Pharma™ Announces US$50 Million Underwritten OfferingWed, 06/24/202606:01 - Helus Pharma
Helus Pharma stock jumps on Phase 3 trial enrollment progress By Investing.com - Investing.com South Africa
Helus Pharma Provides Update on APPROACH Phase 3 Trial Enrollment ProgressWed, 06/24/202606:00 - Helus Pharma
Helus Pharma (HELP) Announces Successful Pricing of $50M Share O - GuruFocus
Helus Pharma (HELP) Reports Significant Progress in Clinical Tri - GuruFocus
Helus Pharma (HELP) Launches $50 Million Public Offering to Fund Clinical Pipeline - GuruFocus
Helus Pharma’s depression drug trial surpasses 86% enrollment - Investing.com UK
Helus Pharma’s depression drug trial surpasses 86% enrollment By Investing.com - Investing.com Australia
Helus Pharma Prices $50 Million Underwritten Offering - Moomoo
Helus Pharma prices $50 million stock offering at $4.85/share By Investing.com - Investing.com India
Helus Pharma Provides Update On Approach Phase 3 Trial Enrollment Progress - TradingView
Helus Pharma prices $50 million stock offering at $4.85/share - Investing.com
HELP Stock Tanks 22% Despite Strong Phase 2 Results For Anxiety Treatment: Retail Buys The Dip Ignoring Market’s Pessimism - Stocktwits
Helus Pharma Inc Stock (HELP) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.64%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):